Intervenční studie k porovnání účinnosti a bezpečnosti tafenochinu (TQ) a primachinu (PQ), když se oba užívají společně s chlorochinem (CQ) pro léčbu malárie P. Vivax u indických účastníků ve věku 2 let a starších
Randomizovaná, otevřená, multicentrická, intervenční studie fáze 3 účinnosti a. Bezpečnost tafenochinu ve srovnání s primaquinem (oba současně podávané s chlorochinem) pro radikální léčbu (prevence relapsu) malárie Plasmodium Vivax (P. Vivax) u indických účastníků (dětská a dospělá populace)
The aim of this study is to collect efficacy and safety data to support the registration of tafenoquine in India.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Fáze 3
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: US GSK Clinical Trials Call Center
- Telefonní číslo: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
Studijní záloha kontaktů
- Jméno: EU GSK Clinical Trials Call Center
- Telefonní číslo: +44 (0) 20 89904466
- E-mail: GSKClinicalSupportHD@gsk.com
Studijní místa
-
-
-
Ahmedabad, Indie, 380008
- Nábor
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonní číslo: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonní číslo: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Vrchní vyšetřovatel:
- Leena Dabhi
-
Bikaner, Indie, 334001
- Nábor
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonní číslo: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonní číslo: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Vrchní vyšetřovatel:
- Sanjay Kumar Kochar
-
Kolkata, Indie, 700073
- Nábor
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonní číslo: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonní číslo: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Vrchní vyšetřovatel:
- Arunansu Talukdar
-
Mumbai, Indie, 400012
- Nábor
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonní číslo: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonní číslo: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Vrchní vyšetřovatel:
- Nithya Gogtay
-
Surat, Indie, 395004
- Nábor
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonní číslo: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonní číslo: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Vrchní vyšetřovatel:
- Shailesh Jethwa
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Males and females >=2 years of age and under (<) 65 years of age, weighing >10 kg.
-
The participant has a positive malarial smear for P. vivax with a parasite density of >100/microliter and <100,000/microliter.
-
The participant has a screening Hb value >8 g/dL.
-
The participant has an axillary temperature of 37.5°C or history of fever 48 hours before recruitment.
-
The participant has a G6PD value (measured using the SD Biosensor STANDARDTM G6PD test) 6.1 units/gram (U/g) Hb for G6PD activity (6.1 U/g Hb cut-off is applicable for both males and females).
-
A female participant is eligible to participate if she is not pregnant or breastfeeding, and if one of the following conditions applies:
- Is a woman of non-childbearing potential (WONCBP) as defined in
- Is a Women of Childbearing Potential (WOCBP) and using a contraceptive method that is highly effective (with a failure rate of <1% per year), with low user dependency, during the study intervention period and for at least 90 days after the last dose of study intervention. The investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the first dose of study intervention. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
-
A WOCBP must test negative on a highly sensitive pregnancy test (urine or serum as required by local regulations) before the first dose of study intervention.
-
The participant is willing and able to comply with the procedures described in the study protocol. The participant or parent/legal guardian, as applicable, has given written informed, dated consent; and the participant has given written assent, if applicable, to participate in the study.
Exclusion Criteria:
-
The participant has severe P. vivax malaria as defined by WHO criteria [WHO, 2023].
-
The participant has a mixed malaria infection (identified by a malarial smear).
-
The participant has a condition that may affect absorption of study medication, such as severe vomiting (no food or inability to take food during the previous 8 hours).
-
The participant has a history of porphyria, psoriasis, or epilepsy.
-
The participant has a history of allergy, intolerance to or a known contraindication to the use of mefloquine (or other aryl amino alcohol drugs), chloroquine, tafenoquine, primaquine, any other 4- or 8-AQ or any of their respective excipients.
-
The participant has received treatment with any investigational drug within 30 days of study entry, or within 5 half-lives, whichever is longer.
-
The participant has previously enrolled in this study.
-
The participant has a recent history of illicit drug abuse or heavy alcohol intake that in the opinion of the investigator could compromise full participation in the study or adherence to study procedures.
-
Participants with a current or past history of serious psychiatric disorders.
-
The participant has a clinically significant concurrent illness (e.g., pneumonia, tuberculosis, meningitis, septicemia, dengue, coagulopathy, severe hemorrhage, or febrile convulsions prior to consent) or a pre-existing condition (e.g., renal disease, malignancy, or severe malnutrition according to WHO child growth standards) or systemic disease predisposing patients to suffer from granulocytopenia, such as rheumatoid arthritis and lupus erythematosus or severe ocular disease.
-
The participant is known to be HIV-infected and/or is currently on antiretroviral therapy.
-
The participant is regularly using drugs with hemolytic potential.
-
The participant has a QT corrected by Fridericia's formula (QTcF) >450 msec, evidence of bradycardia (<50 beats per min) or ventricular arrhythmias on the screening ECG, a history of cardiac disease (e.g., myocardial infarction, congenital heart disease, or arrhythmia), hypokalemia (<2.9 millimoles per liter [mmol/L]) or hyperkalemia (>=6.0 mmol/L) at Screening.
-
The participant has taken drugs with antimalarial activity (e.g., artemisinin-based combination therapies, mefloquine, primaquine, chloroquine, tafenoquine or any other 4-AQ) within 30 days prior to study entry.
-
The participant has taken or will likely require during the study the use of:
- Histamine-2 blockers (restricted to first 3 days whilst receiving CQ)
- Antacids (restricted to first 3 days whilst receiving CQ)
- Drugs of the biguanide class (i.e., phenformin, metformin, buformin)
- Anti-arrhythmic agents (i.e., dofetilide, procainamide, pilsicainide)
- Medications that prolong the QTc interval
-
The participant has liver transaminases (ALT/AST) >2 times the upper limit of normal (ULN).
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: TQ/CQ
Participants in this group receive a single dose of TQ on Day 1 or Day 2 and a single dose of CQ daily, on Days 1 to 3. |
A single dose of TQ will be administered orally on Day 1 or Day 2. A single dose of CQ will be administered orally, daily, on Days 1 to 3. |
|
Aktivní komparátor: PQ/CQ
Participants in this group receive a single dose of PQ daily from Day 1 or 2, up to Day 14 (or Day 15 if PQ started on Day 2) and a single dose of CQ daily, on Days 1 to 3. |
A single dose of CQ will be administered orally, daily, on Days 1 to 3. A single dose of PQ will be administered orally, daily, on Day 1 or 2 to Day 14 (or Day 15 if PQ started on Day 2). |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Number of participants remaining recurrence-free during the 6 months post-treatment and have a negative blood smear at the Month 6 (end of study [EOS]) visit
Časové okno: Up to Month 6
|
Two consecutive negative blood smears between Day 2 and Day 8, no positive blood smear for P. vivax parasites at any point during the 6-month follow-up period, and a negative P. vivax smear at the 6-month assessment. |
Up to Month 6
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Počet úmrtí
Časové okno: Do měsíce 6
|
Do měsíce 6
|
|
|
Laboratorní parametry splňující kritéria 3. stupně >= Division of AIDS (DAIDs).
Časové okno: Do měsíce 6
|
Do měsíce 6
|
|
|
Parametry vitálních funkcí splňující kritéria >=DAIDs Grade 3
Časové okno: Do měsíce 6
|
Do měsíce 6
|
|
|
Změna od výchozí hodnoty při každé studijní návštěvě u hematologických parametrů (procento retikulocytů)
Časové okno: Ve dnech 5, 8, 15, 29, 60, 90, 120, 150 a 180
|
Ve dnech 5, 8, 15, 29, 60, 90, 120, 150 a 180
|
|
|
Number of participants with clinically relevant hemolysis change from baseline
Časové okno: Up to Day 14
|
A decrease in hemoglobin of greater than or equal to (>=) 30% or greater than (>) 3g/deciliter (dL) from baseline; or an overall drop in hemoglobin below 6.0 g/dL or complications thereof (e.g., required transfusions, acute renal failure) are considered clinically relevant hemolysis changes. |
Up to Day 14
|
|
Time to recurrence of P. vivax malaria
Časové okno: Up to Month 6
|
Recurrence is defined as a positive blood smear for P. vivax parasites within the 6-month follow-up period, after clearance of blood-stage parasitemia. |
Up to Month 6
|
|
Number of participants with treatment emergent adverse events (TEAEs) up to Month 6
Časové okno: Up to Month 6
|
An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
Up to Month 6
|
|
Number of participants with TEAEs meeting >= Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 criteria
Časové okno: Up to Month 6
|
Severity was graded according to DAIDS grading criteria, where Grade 1-mild, Grade 2-moderate, Grade 3-severe, Grade 4-potentially life-threatening, Grade 5-Death. |
Up to Month 6
|
|
Number of participants with drug related TEAEs
Časové okno: Up to Month 6
|
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
Up to Month 6
|
|
Number of participants with serious AEs (SAEs)
Časové okno: Up to Month 6
|
A SAE is any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization or result in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant. |
Up to Month 6
|
|
Number of participants with AEs resulting in treatment discontinuation
Časové okno: Up to Month 6
|
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
Up to Month 6
|
|
Number of participants with AEs leading to study withdrawal
Časové okno: Up to Month 6
|
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
Up to Month 6
|
|
Number of participants with AEs considered to be hematologically related
Časové okno: Up to Month 6
|
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
Up to Month 6
|
|
Liver chemistry changes meeting Hy's criteria
Časové okno: Up to Month 6
|
Hy's criteria cases were defined as any elevated alanine aminotransferase (ALT) >=3 times upper limit of normal (ULN) and total bilirubin >=2 times ULN or ALT >=3 times ULN and international normalized ratio (INR) >1.5. |
Up to Month 6
|
|
Number of participants with TEAEs up to Week 4
Časové okno: Up to Week 4
|
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
Up to Week 4
|
|
Change from baseline at each study visit for clinical chemistry parameters (ALT, AST, ALP)
Časové okno: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Data for alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) is measured in international units/liter (IU/L). |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for clinical chemistry parameters (CPK)
Časové okno: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Data for creatine phosphokinase (CPK) is measured in units per liter (U/L). |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for clinical chemistry parameters (total bilirubin, indirect bilirubin, blood urea nitrogen [BUN]/Urea, and serum creatinine)
Časové okno: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Clinical chemistry parameters are measured in milligrams per decilitre (mg/dL). |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for clinical chemistry parameters (serum electrolytes)
Časové okno: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Data for serum electrolytes is measured in millimoles per liter (mmol/L). |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for haematology parameters (platelet count)
Časové okno: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Platelets are measured in number of platelets per microliter (µL). |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for haematology parameters (red blood cell [RBC] count)
Časové okno: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Data for RBC is measured in millions of cells per microliter (number of RBCs x10^6/µL). |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for haematology parameters (mean corpuscular volume [MCV])
Časové okno: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Data for MVC is measured in femtoliters (fL). |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for haematology parameters (mean corpuscular hemoglobin [MCH])
Časové okno: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Data for MCH is measured in picograms (pg) per cell. |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for haematology parameters (white blood cell count [WBC] with differential)
Časové okno: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Data for neutrophils, lymphocytes, monocytes, eosinophils and basophils is presented as a count, which measures a percentage (%) of the WBC. |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for haematology parameters (hemoglobin)
Časové okno: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Hemoglobin is measured in grams per deciliter (g/dL). |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
|
Change from baseline at each study visit for haematology parameters (hematocrit)
Časové okno: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Hematocrit is measured in volume percentage (%) of RBC in blood. |
At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- 208550
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
Časový rámec sdílení IPD
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Kritéria přístupu pro sdílení IPD
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Typ podpůrných informací pro sdílení IPD
- PROTOKOL STUDY
- MÍZA
- ICF
- CSR
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .